Straumann Holding AGWBO:STMN 76 EV-to-FCF is 61.35 as of Jun. 30, 2026, which is 5% below its 10-year median of 64.63. GuruFocus rates WBO:STMN with a GF Score™ of 76/100 and a GF Value™ of €149.34 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 419 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 80.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Straumann Holding AG's Enterprise Value is €18,406 Mil.
Straumann Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €300 Mil. Therefore, Straumann Holding AG's EV-to-FCF for today is 61.35.
The historical rank and industry rank for Straumann Holding AG's EV-to-FCF or its related term are showing as below:
WBO:STMN'
s EV-to-FCF Range Over the Past 10 Years
Min: 31.91 Med: 64.63 Max: 111.16
Current: 60.22
During the past 13 years, the highest EV-to-FCF of Straumann Holding AG was 111.16. The lowest was 31.91. And the median was 64.63.
WBO:STMN's EV-to-FCF is ranked worse than 80.91% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.57
vs WBO:STMN: 60.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Straumann Holding AG (WBO:STMN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Straumann Holding AG's PE Ratio (TTM) for today is calculated as:
Straumann Holding AG's share price for today is €116.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €2.382.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Straumann Holding AG EV-to-FCF Related Terms
Straumann Holding AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's EV-to-FCF falls into.
Straumann Holding AG's current Enterprise Value is €18,406 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Straumann Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €300 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (WBO:STMN) has a EV-to-FCF of 61.35 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Straumann Holding AG and its competitors. This is near median its historical median of 64.63. Over the past decade, Straumann Holding AG's EV-to-FCF has ranged from 31.91 to 111.16. According to the industry distribution chart, Straumann Holding AG ranks #339 out of 419 companies in the Medical Devices & Instruments industry, placing it in the top 80.9%.
Is Straumann Holding AG's EV-to-FCF too high?
Straumann Holding AG's current EV-to-FCF of 61.35 is near median its 10-year median of 64.63. Over the past 10 years, this metric has ranged from a low of 31.91 to a high of 111.16. The Medical Devices & Instruments industry median EV-to-FCF is 22.57. Straumann Holding AG's value of 61.35 is 171.8% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #339 out of 419 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Straumann Holding AG has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #339 out of 419 companies for EV-to-FCF. This places Straumann Holding AG in the lower half of its industry. The industry median EV-to-FCF is 22.57. Straumann Holding AG's value of 61.35 is 171.8% above this benchmark. Historically, Straumann Holding AG's own EV-to-FCF has ranged from 31.91 to 111.16 over the past decade. While the company's 10-year median is 64.63 vs. the industry median of 22.57, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.57, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current EV-to-FCF of 61.35 is 171.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current EV-to-FCF is 61.35, which is near median its own 10-year median of 64.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (WBO:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is €149.34, compared to a current price of €116.00 — trading 22.3% below its estimated fair value. The current EV-to-FCF is 61.35, which is near median its 10-year median of 64.63 and 171.8% above the Medical Devices & Instruments industry median of 22.57. Straumann Holding AG's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Straumann Holding AG (WBO:STMN), the current EV-to-FCF is 61.35 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (WBO:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of €116.00 is trading 22.3% below its estimated GF Value™ of €149.34.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for WBO:STMN:
EV-to-FCF: 61.35 (near median its 10-year median of 64.63)
GF Value™: €149.34 vs. price of €116.00 (22.3% below fair value)
Industry Position: 171.8% above the Medical Devices & Instruments median (#339 of 419)
No single metric tells the full story. See the WBO:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
76GF Score
Get the complete analysis for WBO:STMN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:STMN has been successfully added to your 
